MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Vaxart, Inc. (NASDAQ: VXRT)*
Organization & Developments: Vaxart
Parents
Vaxart, Inc. (NASDAQ: VXRT)*
Children
2020: Vaxart Oral COVID-19 Vaccine Joins Trump's "Warp Speed," Ramps Up Manufacturing Capacity
2020: Vaxart was served a grand jury subpoena in July over its controversial role in OWS-funded preclinical study
2020: Vaxart: A Retail Shareholder's Perspective
2020: Vaxart: A Speculative Buy For Its Oral COVID-19 Vaccine
2020: Vaxart: A Strong Buy For Their Oral Tablet Covid-19 Vaccine
2020: Vaxart: Practical COVID-19 Oral Pill For 2021
2020: Vaxart's Technology Could Be A COVID-19 Game Changer
2021: Plucky Underdog Vaxart Still Banging Drum For Oral Vaccination
2021: Vaxart: A Close Look At Their COVID-19 Oral Tablet Vaccine Program
2021: Vaxart: Stock Drop Following Phase 1 Data For Oral COVID-19 Vaccine Is A Buying Opportunity
2021: Vaxart's No-Shot Model Is A Long Shot
2022: Vaxart: The Market Still Isn't Buying Oral Vaccine Thesis_seekingalpha.com
2024: Vaxart receives BARDA-funded project award up to $453M
2025: Layoffs, shutdowns and billions up in smoke. What's wrong with Bay Area biotech?
2025: Vaxart lays off 10% of staff after HHS unexpectedly demands halt to COVID vaccine trial
Jumps
*Key People: Vaxart
Finance & Acquisitions: Vaxart